INGN 251

Drug Profile

INGN 251

Alternative Names: Ad-PTEN; Adenoviral-PTEN; PTEN gene therapy

Latest Information Update: 07 Feb 2005

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cancer Research Technology
  • Developer Cancer Research Technology; Introgen Therapeutics; Texas Heart Institute
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Brain cancer; Cardiovascular disorders; Colorectal cancer; Malignant melanoma; Urogenital cancer

Most Recent Events

  • 07 Feb 2005 Discontinued - Preclinical for Brain cancer in United Kingdom (unspecified route)
  • 07 Feb 2005 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 07 Feb 2005 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top